Abstract

The Gleason grading system, currently the most powerful prognostic predictor of prostate cancer, is based solely on the tumor’s histological architecture and has high inter-observer variability. We propose an automated Gleason scoring system based on deep neural networks for diagnosis of prostate core needle biopsy samples. To verify its efficacy, the system was trained using 1133 cases of prostate core needle biopsy samples and validated on 700 cases. Further, system-based diagnosis results were compared with reference standards derived from three certified pathologists. In addition, the system’s ability to quantify cancer in terms of tumor length was also evaluated via comparison with pathologist-based measurements. The results showed a substantial diagnostic concordance between the system-grade group classification and the reference standard (0.907 quadratic-weighted Cohen’s kappa coefficient). The system tumor length measurements were also notably closer to the reference standard (correlation coefficient, R = 0.97) than the original hospital diagnoses (R = 0.90). We expect this system to assist pathologists to reduce the probability of over- or under-diagnosis by providing pathologist-level second opinions on the Gleason score when diagnosing prostate biopsy, and to support research on prostate cancer treatment and prognosis by providing reproducible diagnosis based on the consistent standards.

Highlights

  • Prostate cancer is a leading type of cancer in men worldwide

  • We report its performance compared to the results of a multi-institutional reference standard established by certified pathologists and its ability to quantify cancer in terms of tumor length compared with pathologist-based measurements

  • The proposed system performance according to grade groups showed that the system achieved a higher diagnostic concordance to the reference standard (0.907 in quadratic-weighted kappa) compared to the original hospital diagnoses (0.870) in the validation dataset

Read more

Summary

Introduction

Prostate cancer is a leading type of cancer in men worldwide. Core needle biopsy is the main method for diagnosis of prostate cancer and recommended to patients whose results from initial screening tests (e.g., a prostate-specific antigen test, and digital rectal exam) are suspicious of prostate cancer [2]. The management of prostate cancer differs depending on the patients’ life expectancy, prostate-specific antigen level, and Gleason score. The Gleason score is a grading system widely used for evaluating prostate cancer tissues and is the standard for prognosis prediction and treatment selection. It was first developed by Donald Gleason and the Veterans’ Administration Cooperative Urologic Research Group between 1966 and 1974.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call